Wall Street analysts expect that Humana Inc (NYSE:HUM) will post sales of $14.12 billion for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Humana’s earnings, with the highest sales estimate coming in at $14.32 billion and the lowest estimate coming in at $13.96 billion. Humana posted sales of $13.76 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 2.6%. The firm is expected to report its next earnings report on Wednesday, May 2nd.
On average, analysts expect that Humana will report full year sales of $14.12 billion for the current year, with estimates ranging from $55.63 billion to $56.19 billion. For the next fiscal year, analysts forecast that the company will report sales of $59.97 billion per share, with estimates ranging from $59.07 billion to $60.65 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Humana.
Humana (NYSE:HUM) last issued its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, topping the consensus estimate of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The business had revenue of $13.19 billion for the quarter, compared to analyst estimates of $13.14 billion. During the same quarter last year, the company earned $2.34 EPS. The business’s quarterly revenue was up 2.4% on a year-over-year basis.
In other Humana news, SVP Brian P. Leclaire sold 1,679 shares of Humana stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $245.97, for a total value of $412,983.63. Following the transaction, the senior vice president now directly owns 9,888 shares in the company, valued at approximately $2,432,151.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Cynthia H. Zipperle sold 1,196 shares of Humana stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $273.33, for a total value of $326,902.68. Following the completion of the transaction, the senior vice president now owns 7,771 shares in the company, valued at $2,124,047.43. The disclosure for this sale can be found here. Insiders sold a total of 41,775 shares of company stock worth $11,169,845 over the last quarter. Company insiders own 0.60% of the company’s stock.
Several hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC boosted its stake in shares of Humana by 74.1% in the third quarter. Janus Henderson Group PLC now owns 2,729,248 shares of the insurance provider’s stock valued at $664,921,000 after buying an additional 1,161,661 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Humana by 11.4% in the fourth quarter. Wells Fargo & Company MN now owns 1,842,029 shares of the insurance provider’s stock valued at $456,951,000 after buying an additional 188,711 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Humana by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,522,654 shares of the insurance provider’s stock valued at $376,937,000 after buying an additional 28,147 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Humana by 10.8% in the third quarter. Ameriprise Financial Inc. now owns 1,465,119 shares of the insurance provider’s stock valued at $356,960,000 after buying an additional 142,706 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of Humana by 3.0% in the fourth quarter. Acadian Asset Management LLC now owns 1,043,303 shares of the insurance provider’s stock valued at $258,809,000 after buying an additional 30,812 shares in the last quarter. Institutional investors own 97.85% of the company’s stock.
Shares of Humana (NYSE:HUM) traded down $4.18 during midday trading on Wednesday, hitting $268.21. The stock had a trading volume of 1,050,000 shares, compared to its average volume of 1,080,000. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.48. Humana has a 1-year low of $203.48 and a 1-year high of $293.35. The firm has a market cap of $36,930.00, a price-to-earnings ratio of 15.23, a PEG ratio of 1.48 and a beta of 0.95.
Humana declared that its Board of Directors has authorized a stock repurchase plan on Thursday, December 14th that authorizes the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization authorizes the insurance provider to purchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its stock is undervalued.
The company also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be given a dividend of $0.50 per share. This is a positive change from Humana’s previous quarterly dividend of $0.40. The ex-dividend date is Wednesday, March 28th. This represents a $2.00 annualized dividend and a yield of 0.75%. Humana’s payout ratio is 9.09%.
ILLEGAL ACTIVITY NOTICE: “Analysts Anticipate Humana Inc (HUM) Will Announce Quarterly Sales of $14.12 Billion” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2018/03/12/analysts-anticipate-humana-inc-hum-will-announce-quarterly-sales-of-14-12-billion.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.